Pancreatic cancer is currently the fourth leading cause of cancer-related deaths in the United States, following lung cancer and breast cancer and seventh leading cause of cancer related deaths worldwide with 432,242 related deaths being reported in 2018. Pancreatic adenocarcinoma (PDAC), classified as an exocrine pancreatic cancer, is considered to be the most common type of pancreatic cancer, accounting for 80% of all pancreatic cancer diagnoses.
The treatment paradigm for pancreatic cancer is predominantly composed of chemotherapies, most notably FOLFIRINOX and gemcitabine-based therapies, which are considered to be gold standard for pancreatic cancer. In patients exhibiting genetic mutations, targeted therapies such as Vitrakvi (larotrectinib), Rozlytrek (entrectinib), Poly (ADP-ribose) polymerase (PARP) inhibitor Lynparza (olaparib), and Keytruda (pembrolizumab) are currently included in treatment guidelines across the 8MM. CP-613 (devimistat) is the lead pipeline candidate in 1L setting. This indication will also se introduction of 2 strong pipeline agents in 3L setting.
KEY QUESTIONS ANSWERED
• Nine late-stage pipeline agents are going to enter the pancreatic cancer market from 2019 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
• What are the current unmet needs in pancreatic cancer, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
• What is the market outlook in the 8MM from 2019-2029? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
• What are the main corporate trends? Who are the current and future players?
Overview of pancreatic cancer including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Topline pancreatic cancer market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting pancreatic cancer therapeutics sales in the 8MM.
Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase III).
Analysis of the current and future market competition in the global pancreatic cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
The main drivers of growth include the anticipated approval and launch of 9 pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM during the forecast period.
The main barriers to growth in the 8MM include the patent expiry of major brands and the high price of premium priced therapeutics entering the market.
Among the late-stage pipeline products and marketed agents, CP-613 (devimistat) and Masiviera (masitinib) are expected to generate the greatest revenues over the forecast period.
The most important unmet needs in the pancreatic cancer market include: effective treatment options that prolong survival in advanced or metastatic settings, early diagnosis and tumor targeting drugs with novel mechanisms of actions.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
Develop business strategies by understanding the trends shaping and driving the global pancreatic cancer therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global pancreatic cancer market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global pancreatic cancer therapeutics market from 2019-2029.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Merrimack Pharmaceuticals / Baxalta
Merck & Co
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Pancreatic Cancer: Executive Summary
2.1 Global Pancreatic Cancer Market Expected to Grow at
8.2% CAGR to $4.1B During 2019–2029
2.2 Assessing Viability of Novel Tumor Targeting Therapies – A Key Focus of Current Clinical Development
2.3 Lack of Effective Treatment Options – Highest Unmet Need in PDAC
2.4 High Opportunity for Pipeline Agents Demonstrating Increased Overall Survival
2.5 Targeted Therapies Provide a Brighter Outlook for PDAC
2.6 What Do Physicians Think?
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Classification or Staging Systems
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used
5.4.2 Forecast Assumptions and Methods
5.4.3 Diagnosed Incident Cases of Pancreatic Cancer and PDAC
5.4.4 Diagnosed Incident Cases of PDAC by Stages
5.4.5 Diagnosed Incident Cases of PDAC by Familial PDAC by Germline Mutation
5.4.6 Diagnosed Incident Cases of PDAC by KRAS and NTRK Gene Fusion Mutation
5.4.7 Diagnosed Incident Cases of PDAC by PD-L1 Expression
5.4.8 Five-Year Diagnosed Prevalent Cases of PDAC
5.5 Epidemiological Forecast for Pancreatic Cancer, 2019–2029
5.5.1 Diagnosed Incident Cases of Pancreatic Cancer
5.5.2 Diagnosed Incident Cases of PDAC
5.5.3 Sex-Specific Diagnosed Incident Cases of PDAC
5.5.4 Age-Specific Diagnosed Incident Cases of PDAC
5.5.5 Diagnosed Incident Cases of PDAC by Stage at Diagnosis
5.5.6 Diagnosed Incident Cases of Familial PDAC by Germline Mutations
5.5.7 Diagnosed Incident Cases of PDAC by KRAS and NTRK Gene Mutations
5.5.8 Diagnosed Incident Cases of PDAC by PD-L1 Expression
5.5.9 Five-Year Diagnosed Prevalent Cases of PDAC
5.6.1 Epidemiological Forecast Insight
5.6.2 COVID-19 Impact
5.6.3 Limitations of Analysis
5.6.4 Strengths of Analysis
6 Current Treatment Options
7 Unmet Needs and Opportunity Assessment
7.2 Early Detection
7.3 Expansion of Eligible Patient Population and Need for the Discovery of New Biomarkers
7.4 Increased Availability of Treatment Options
7.5 Treatment Options in the Third-Line Setting
7.6 Prolonged Life Expectancy/Survival
8 R&D Strategies
8.1.1 Drugs Targeting Tumor Immune Evasion Mechanisms
8.1.2 Expansion into Neoadjuvant and Adjuvant Settings
8.1.3 Explore Viability of Novel Targets and Mechanism of Action
8.1.4 Reformulation of Marketed Drugs
8.1.5 Therapy Sequencing
8.2 Clinical Trials Design
8.2.1 Key Clinical Trials
8.2.2 Primary and Secondary Endpoints
8.2.3 Trial Design Characteristics
9 Pipeline Assessment
9.2 Innovative Early-Stage Approaches
9.2.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy
9.2.2 Gene therapy
9.2.3 Cancer vaccine
9.3 Other Drugs in Development
10 Pipeline Valuation Analysis
10.1 Clinical Benchmark of Key Pipeline Drugs
10.2 Commercial Benchmark of Key Pipeline Drugs
10.3 Competitive Assessment
10.4 Top-Line 10-Year Forecast
10.4.4 Urban China
11.4.1 Forecasting Methodology
11.4.2 Diagnosed Patients
11.4.3 Percent Drug-Treated Patients
11.4.4 Drugs Included in Each Therapeutic Class
11.4.5 Launch and Patent Expiry Dates
11.4.6 General Pricing Assumptions
11.4.7 Individual Drug Assumptions
11.4.8 Generic Erosion
11.4.9 Pricing of Pipeline Agents
11.5 Primary Research
11.6 Primary Research – Prescriber Survey
11.7 About the Authors
11.7.2 Therapy Area Director
11.7.4 Managing Epidemiologist
11.7.5 Global Director of Therapy Analysis and Epidemiology
11.7.6 Global Head and EVP of Healthcare Operations and Strategy
11.8 About GlobalData
11.9 Contact Us
List of Tables
Table 1: Pancreatic Cancer: Key Metrics in the 8MM
Table 2: Selected Genetic Syndromes with Associated Pancreatic Cancer Risk
Table 3: AJCC TNM classification System for Pancreatic Cancer
Table 4: AJCC TNM Staging System for Pancreatic Cancer
Table 5: Risk Factors and Comorbidities for PDAC
Table 6: Current Leading Treatments for Pancreatic Cancer, 2019
Table 7: Key Pipeline Agents in Development for Pancreatic cancer, 2019-2029
Table 8: Key Phase II/III Clinical Trials in Pancreatic Cancer, 2019-2029
Table 9: Comparison of Therapeutic Classes in Development for Pancreatic Cancer, 2019–2029
Table 10: Leading Pharmaceutical Companies Innovating in CAR-T Therapy in 2019
Table 11: Drugs in Development for Pancreatic Cancer, 2019–2029
Table 12: Clinical Benchmarking of Key Marketed & Pipeline Products – First Line
Table 13: Clinical Benchmarking of Key Marketed & Pipeline Products – Second Line
Table 14: Commercial Benchmarking of Key Marketed & Pipeline Products – First Line
Table 15: Commercial Benchmarking of Key Marketed & Pipeline Products – Second Line
Table 16: Key Events Impacting Sales for Pancreatic Cancer in the US, 2019–2029
Table 17: Pancreatic Cancer Market – Global Drivers and Barriers, 2019–2029
Table 18: Key Historical and Projected Launch Dates for Pancreatic Cancer
Table 19: Key Historical and Projected Patent Expiry Dates for Pancreatic Cancer
Table 20: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for Pancreatic Cancer in 2019 and 2029
Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care, FOLFIRINOX – First Line
Figure 3: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Commonly Used Therapies, Gemcitabine + Abraxane and Onivyde
Figure 4: 8MM, Diagnosed Incidence of PDAC, Men, Ages ≥18 Years, 2009–2029, Cases Per 100,000 Population
Figure 5: 8MM, Diagnosed Incidence of PDAC, Women, Ages ≥18 Years, 2009–2029, Cases Per 100,000 Population
Figure 6: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of Pancreatic Cancer and PDAC
Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of PDAC by Stage at Diagnosis
Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Familial PDAC by Germline Mutation
Figure 9: 8MM, Sources Used to Forecast of PDAC by KRAS and NTRK Gene Fusion Mutation
Figure 10: 8MM, Sources Used to Forecast the PD-L1 Expression of PDAC
Figure 11: 8MM, Sources Used to Forecast Five-Year Diagnosed Prevalent Cases of PDAC
Figure 12: 8MM, Diagnosed Incident Cases of Pancreatic Cancer, Both Sexes, Ages ≥18 Years, N, 2019
Figure 13: 8MM, Diagnosed Incident Cases of PDAC, Both Sexes, Ages ≥18 Years, N, 2019
Figure 14: 8MM, Diagnosed Incident Cases of PDAC, by Sex, Ages ≥18 Years, N, 2019
Figure 15: 8MM, Diagnosed Incident Cases of PDAC by Age, Both Sexes, N, 2019
Figure 16: 8MM, Diagnosed Incident Cases of PDAC by Stage at Diagnosis, Ages ≥18 Years, Both Sexes, N, 2019
Figure 17: 8MM, Diagnosed Incident Cases of Familial PDAC by Germline Mutations, Ages ≥18 Years, Both Sexes, N, 2019
Figure 18: 8MM, Diagnosed Incident Cases of PDAC by KRAS and NTRK Gene Fusion Mutations, Ages ≥18 Years, Both Sexes, N, 2019
Figure 19: 8MM, Diagnosed Incident Cases of PDAC by PD-L1 Expression, Ages ≥18 Years, Both Sexes, N, 2019
Figure 20: 8MM, Five-Year Diagnosed Prevalent Cases of PDAC, Ages ≥18 Years, Both Sexes, N, 2019
Figure 21: Unmet Needs and Opportunities in Pancreatic Cancer, 2020
Figure 22: Overview of Development Pipeline in Pancreatic Cancer
Figure 23: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for Pancreatic Cancer in the 8MM During the Forecast Period
Figure 24: Competitive Assessment of Key Pipeline Products – First Line
Figure 25: Competitive Assessment of Key Pipeline Products – Second Line
Figure 26: Global Sales Forecast by Country for Pancreatic Cancer in 2019 and 2029
Figure 27: Global Sales Forecast by Class for Pancreatic Cancer in 2019 and 2029
Figure 28: Sales Forecast by Class for Pancreatic Cancer in the US in 2019 and 2029
Figure 29: Sales Forecast by Class for Pancreatic Cancer in the 5EU in 2019 and 2029
Figure 30: Sales Forecast by Class for Pancreatic Cancer in the Japan in 2019 and 2029
Figure 31: Sales Forecast by Class for Pancreatic Cancer in Urban China in 2019 and 2029